Biomaterial Database

Treatment of severe psoriasis with systemic drugs. 1995

C Camisa

Psoriasis, a common papulosquamous skin disease of unknown cause, affects 2% of the U.S. population with 150,000-200,000 new cases annually. Systemic drug treatment of severe psoriasis includes retinoids, methotrexate, cyclosporine, hydroxyurea, sulfasalazine, and calcitriol. It is important for dermatology nurses to understand the effects of these medications when treating patients who have severe psoriasis.

UI	MeSH Term	Description	Entries
D010353	Patient Education as Topic	The teaching or training of patients concerning their own health needs.	Education of Patients,Education, Patient,Patient Education
D011565	Psoriasis	A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016903	Drug Monitoring	The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.	Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug